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ABSTRACT
Background. Arteriovenous ﬁstulas (AVFs) are the preferred
vascular access type in most hemodialysis patients. However,
the optimal vascular access type in octogenarians and older
(80 years) hemodialysis patients remains widely debated given
their limited life expectancy and lower AVFmaturation rates.
Methods. Among incident hemodialysis patients receiving care
in a large national dialysis organization during 2007–2011, we
examined patterns of vascular access type conversion in 1 year
following dialysis initiation in patients<80 versus80 years of
age. Among a subcohort of patients 80 years of age, we exam-
ined the association between vascular access type conversion
andmortality using multivariable survival models.
Results. In the overall cohort of 100 804 patients, the prevalence
of AVF/arteriovenous graft (AVG) as the primary vascular ac-
cess type increased during the ﬁrst year of hemodialysis, but pla-
teaued thereafter. Among 8356 patients 80 years of age and
treated for >1 year, those with initial AVF/AVG use and place-
ment of AVF from a central venous catheter (CVC) had lower
mortality compared with patients with persistent CVC use.
When the reference group was changed to patients who had
AVF placement from a CVC in the ﬁrst year of dialysis, those
with initial AVF use had similar mortality. A longer duration of
CVC use was associated with incrementally worse survival.
Conclusions. Among incident hemodialysis patients 80 years
of age, placement of an AVF from a CVC within the ﬁrst year of
dialysis had similar mortality compared with initial AVF use. Our
data suggest that initial CVC use with later placement of an AVF
may be an acceptable option among elderly hemodialysis patients.
Keywords: elderly, hemodialysis, mortality, tunneled dialysis
catheter, vascular access
INTRODUCTION
In the USA, there has been a rapid rise in the number of elderly
patients with end-stage renal disease, who may require different
management approaches compared with their nonelderly coun-
terparts [1–3]. Among elderly hemodialysis patients 80 years
of age, there remain substantial knowledge gaps with respect to
the optimal vascular access type in these patients [4, 5]. While
associated with better clinical outcomes in the general hemodi-
alysis population [6–9], use of arteriovenous fistulas (AVFs) in
elderly hemodialysis patients poses unique challenges given
their higher rates of inadequate maturation of vascular access
and limited life expectancy [10–12]. Moreover, there remains
wide debate as to whether the Fistula First Breakthrough
Initiative should be applied to the elderly hemodialysis popula-
tion [12–15], given operational risks, longer maturation times
and emerging data indicating the lack of a survival benefit com-
pared with tunneled dialysis catheter [central venous catheter
(CVC)] and/or arteriovenous graft (AVG) use in elderly
patients [16–18].
As the vast majority of incident hemodialysis patients initi-
ate dialysis with CVCs as their primary vascular access (70–
80%) [19], which may be more common in the elderly, it
remains unknown as to whether particular patterns of vascular
access use in the early phases of dialysis, including placement of
AVFs/AVGs from a CVC, are associated with differential mor-
tality risk in patients80 years of age. Thus we sought to exam-
ine patterns of vascular access use within the first year of
dialysis among a large, contemporary cohort of incident hemo-
dialysis patients stratified by age from a large national dialysis
organization (<80 versus 80 years). We additionally investi-
gated whether specific patterns of vascular access use within the
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first year of dialysis were associated with differential survival
among hemodialysis population80 years of age.
MATERIALS AND METHODS
Source population
We conducted a historical cohort study of incident hemodi-
alysis patients receiving care from a large dialysis organization
in the USA with comprehensive capture of longitudinal data on
patients’ sociodemographics, comorbidities, laboratory tests
and clinical characteristics. The original source population was
a cohort of 208 820 incident dialysis patients receiving care in
one of the large dialysis organization outpatient facilities over a
5-year period (from January 2007 to December 2011). Patients
included were those18 years old, received hemodialysis for at
least 60 days and had available vascular access type data for
at least 1 year after dialysis initiation. Patients excluded were
those who were receiving a dialysis modality other than in-
center hemodialysis or had missing vascular access data. The
study was approved by the Institutional Review Committees of
the Los Angeles Biomedical Research Institute at Harbor-
UCLA and the University of California IrvineMedical Center.
Exposure ascertainment
In primary analyses, we sought to examine the association
between patterns of vascular access use within the first year of
hemodialysis and all-cause mortality risk. Longitudinal vascular
access type data updated quarterly were obtained from the
large dialysis organization database. Patients were categorized
according to their patterns of vascular access use: CVC only,
CVC to AVF, CVC to AVG, initial AVF use and initial AVG
use. Patients with initial AVF or initial AVG use included those
who may have transitioned to an alternative vascular access
type during the first year of hemodialysis. In sensitivity analyses
we also examined the association of the duration of CVC use
with all-cause mortality risk. The duration of CVC use was cate-
gorized as follows: <3months, 3–6months, 6–9months and
>9–12months.
Sociodemographic, dialysis treatment and laboratory
characteristics
Information regarding sociodemographics as well as comor-
bidities defined by International Classification of Diseases,
Revision 9 codes were also obtained from the large dialysis orga-
nization database. The Deyo-modified Charlson Comorbidity
Index that excluded the presence or absence of kidney disease
was estimated from these data [20, 21].
Laboratory tests were measured from blood samples col-
lected predialysis except for postdialysis serum urea nitrogen,
and samples were transported to a central laboratory (Deland,
FL, USA), typically within 24 h, where they were measured us-
ing automated and standardized methods. Most laboratory tests
were measured monthly, including serum creatinine, albumin,
white blood cell (WBC) count, total iron binding capacity
(TIBC), calcium, phosphorus and bicarbonate. Serum intact
parathyroid hormone (iPTH) was usually measured at least
once per quarter. Hemoglobin was measured weekly to
biweekly. Delivered dialysis dose was calculated by single-pool
Kt/V using estimating equations. To minimize measurement
variability, all repeated measures for each 91-day interval from
the date of dialysis initiation were averaged and quarterly mean
values in each quarter were used in all analyses.
Outcome ascertainment
The primary outcome of interest was all-cause death.
Patients were censored for kidney transplantation, transfer to a
nonaffiliated dialysis unit, transfer to an alternative dialysis mo-
dality other than in-center thrice-weekly hemodialysis, discon-
tinuation of dialysis, recovery from dialysis treatment or at the
end of the study period (31 December 2011).
Statistical analysis
We first examined patterns of vascular access type over time
in the overall cohort and stratified by age (<80 versus
80 years). Among incident hemodialysis patients 80 years
old who survived the first year of dialysis, we then examined the
association between the various patterns of vascular access use
within the first year of treatment and all-cause mortality risk us-
ing Cox regression models with four levels of adjustment:
(i) Unadjusted model: included pattern of vascular access
use.
(ii) Case mix–adjusted model: included age, sex, race/eth-
nicity, primary insurance type, comorbidities (diabetes
mellitus, hypertension, atherosclerotic heart disease,
congestive heart failure, other cardiovascular disease,
cerebrovascular disease, dyslipidemia, chronic obstruc-
tive pulmonary disease, liver disease and history of ma-
lignancy) and dialysis dose as measured by single-pool
Kt/V.
(iii) Case mixþmalnutrition inﬂammation cachexia syn-
drome (MICS) model: included the case mix–adjusted
model covariates, as well as body mass index (BMI) and
clinically relevant laboratory variables [WBC count, he-
moglobin, serum albumin, creatinine, bicarbonate, cal-
cium, phosphorus, iPTH, total iron binding capacity
and normalized protein catabolic rate (nPCR)].
(iv) Case mixþ albumin model: included the case mix–ad-
justed model covariates and serum albumin.
We a priori defined the case mixþ albumin model as our
preferred model to avoid overadjustment even in the group
with the smallest number of patients while including core con-
founders for the association between patterns of vascular access
and outcomes. The case mixþMICS model was designated as
an exploratory model, which included confounders as well as
potential causal pathway intermediates of the vascular access
type–mortality association. We also examined the vascular ac-
cess type–mortality association across clinically relevant
subgroups.
There was <1% missing data for all covariates, except BMI
(2%), hemoglobin (3%), calcium (5%), phosphorus (5%), WBC
(6%), serum albumin (6%), bicarbonate (6%), single-pool Kt/V
(6%), nPCR (6%), TIBC (8%), iPTH (8%) and serum creatinine
(10%). Missing data were addressed using multiple imputation.
Proportional hazards assumptions were checked by graphical
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testing. All analyses and figures were carried out with Stata
MP, version 13.1 (StataCorp, College Station, TX, USA) and
SigmaPlot, version 12.5 (Systat Software, San Jose, CA, USA).
RESULTS
Overall cohort: patterns of access type within the first
year of dialysis
Among 100 804 patients who met eligibility criteria there
were 52 113, 86 698 and 14 106 patients <65, 65–80 and
80 years of age, respectively (Supplementary data, Figure S1).
In the overall cohort, 80%, 16% and 4% of patients initiated he-
modialysis with a CVC, AVF and AVG, respectively. When
patients were separately examined as those <65, 65–80 and
80 years of age, we observed a similar prevalence of CVC use
(81, 78 and 79%, respectively), AVF use (15, 17 and 16%, re-
spectively) and AVG use (3, 5 and 5%, respectively).
When we compared patterns of vascular access use within
the first year of hemodialysis, we observed a similar pattern
of placement of AVFs/AVGs from CVCs among patients <65,
65–80 and 80 years of age (Figure 1). A significant proportion
of patients persisted in using a CVC even after 1 year in patients
<65, 65–80 and80 years of age (23, 24 and 27%, respectively),
and a lower proportion of patients 80 years of age underwent
placement of an AVF from a CVC after 1 year (patients <65,
65–80 and 80 years of age: 45, 40 and 36%, respectively) and
over the entire study period.
Elderly subcohort: baseline characteristics according to
patterns of access type
We then examined patterns of access type among a subco-
hort of 8326 patients 80 years of age who survived at least 1
year of dialysis. Over the first year of dialysis treatment we ob-
served that 27% of patients persisted in CVC use only, 36%
underwent placement of an AVF from a CVC, 13% underwent
placement of an AVG from a CVC, 18% used an AVF initially
and 6% used an AVG initially (Table 1). Compared with other
patients, particularly those who used an AVF initially, those
who persisted in having a CVC only tended to be female; were
less likely to be Caucasian and more likely to be African
American; were more likely to have Medicare/Medicaid as their
primary insurance; were more likely to have diabetes,
A B
C
FIGURE 1: Patterns of vascular access use over time among incident hemodialysis patients (A) <65 years (n¼ 52 113), (B) 65–80 years
(n¼ 34 585) and (C) 80 years of age (n¼ 14 106).
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atherosclerotic heart disease, congestive heart failure or other
cardiovascular diseases and had lower BMI levels.
Elderly subcohort: patterns of access type and mortality
risk
We then sought to examine the association between patterns
of access type and mortality risk among the aforementioned
subcohort of patients 80 years of age who survived at least 1
year of dialysis. Among these patients, there were 3410 deaths
over a follow-up period of 9808 person-years. The median
follow-up was 23 (interquartile range 17–34) months. In case
mixþ albumin–adjusted analyses (‘primary analyses’), com-
pared to patients with persistent CVC use, those with initial
AVF use, placement of an AVF from a CVC and initial AVG
use had lower mortality risk, whereas those with placement of
an AVG from a CVC had similar mortality risk (Figure 2 and
Supplementary data, Table S2). When the reference group was
changed to patients with placement of an AVF from a CVC,
those with initial AVF use had similar mortality risk {hazard ra-
tio [HR] 0.92 [95% confidence interval (CI) 0.82–1.02]},
whereas those with placement of an AVG from a CVC had
worse survival [HR 1.14 (95% CI 1.01–1.27)]. Patients<65 and
65–80 years of age showed a similar association of mortality
risk with access conversion within 1 year of dialysis. Those with
initial AVF or AVG use and placement of an AVF from a CVC
had lower mortality risk compared with patients exclusively us-
ing a CVC within 1 year of dialysis in case mixþ albumin–ad-
justed analyses. However, it was different from patients
80 years of age, in that patients with placement of an AVF
from a CVC had worse survival compared with initial AVF use
in both age groups [HR 1.13 (95% CI 1.04–1.24) and 1.27
(1.17–1.37), respectively; Supplementary data, Figure S2].
Table 1. Baseline characteristics among incident hemodialysis patients 80 years of age stratiﬁed by patterns of vascular access type during the ﬁrst year of
dialysis
Overall cohort CVC only CVC to AVF CVC to AVG Initial AVF Initial AVG
Patients, n (%) 8326 (100) 2245 (27) 3018 (36) 1063 (13) 1511 (18) 489 (6)
Age (years), mean6 SD 84.9 6 3.3 85.3 6 3.5 84.7 6 3.1* 85.2 6 3.2 84.6 6 3.1* 84.7 6 3.2*
Female, % 46 55 39* 57 33* 58
Race/ethnicity, %
Non-Hispanic Caucasian 66 65 70* 58* 73* 52*
African American 18 20 14* 25* 13* 32*
Hispanic 9 9 9 9 8 7
Asian 4 3 4 4 4 5
Cause for ESRD, %
Diabetes mellitus 33 33 33 35 30 34
Hypertension 44 45 43 42 47 48
Chronic glomerulonephritis 7 6 8 8 7 4
Primary insurance, %
Medicare/ Medicaid 74 75 74 79* 69* 73
Comorbidities, %
Diabetes mellitus 53 53 52 56 49* 58
Hypertension 59 60 59 58 60 61
Atherosclerotic heart disease 18 20 17* 16* 17* 16*
Congestive heart failure 38 39 38 42 34* 37
Cerebrovascular disease 2 2 2 3 2 1
Other cardiovascular disease 19 21 18* 21 16* 14*
Dyslipidemia 29 28 29 28 29 30
Cancer 3 3 3 3 4 3
COPD 6 6 6 6 4* 4
Liver disease 1 1 1 2* 1 0
Charlson comorbidity index 7 (6–8) 7 (6–8) 7 (6–8) 7 (6–8) 7 (6–8) 7 (6–8)
Total CVC use for 1
year after HD, days, median (IQR)
204 (84–338) 358 (337–364) 197 (139–264)* 161 (106–236)* 0 (0–0)* 0 (0–29)*
Body mass index, median (IQR) 24.1 (21.4– 27.2) 23.5 (20.6– 26.8) 24.3 (21.6–27.4)* 24.3 (21.4–27.8)* 24.2 (21.9–27.3)* 24.4 (21.8–27.3)*
Hgb (g/dL), mean6 SD 11.56 0.9 11.66 1.0 11.56 0.9 11.56 0.9 11.56 0.8 11.56 0.9*
WBC count (103/mL), mean6 SD 7.36 2.9 7.76 3.4 7.36 3.1* 7.36 2.4* 6.96 2.1* 7.06 2.2*
Albumin (g/dL), mean6 SD 3.76 0.4 3.66 0.4 3.76 0.4* 3.66 0.4* 3.86 0.4* 3.76 0.4*
Creatininie (mg/dL), mean6 SD 5.76 1.9 5.46 1.9 5.86 1.9* 5.66 1.8 6.06 1.8* 5.96 1.8*
Bicarbonate (mmol/dL), mean6 SD 23.86 2.8 24.06 2.9 23.76 2.8* 23.96 3.0 23.86 2.8 23.96 2.7
Calcium (mg/dL), mean6 SD 8.86 0.5 8.86 0.6 8.86 0.5 8.86 0.5 8.96 0.5* 8.96 0.5
Phosphorus (mg/dL), mean6 SD 4.66 1.0 4.76 1.1 4.66 1.0 4.56 1.0* 4.66 0.9 4.66 1.0
iPTH (ng/mL), median (IQR) 230 (162–313) 232 (156–324) 220 (155–299)* 227 (161–305)* 244 (178–327) 247 (174–326)
TIBC (mg/dL), mean6 SD 2126 42 2036 44 2146 40* 2116 43* 2196 39* 2126 43*
nPNA (g/kg/day), mean6 SD 0.976 0.26 0.946 0.26 0.996 0.26* 0.976 0.27* 0.996 0.25* 0.966 0.25
Single-pool Kt/V, mean6 SD 1.686 0.31 1.646 0.31 1.686 0.31* 1.736 0.33* 1.706 0.29* 1.736 0.27*
*P< 0.05 compared with CVC only.
ESRD, end-stage renal disease; Hgb, hemoglobin; IQR, interquartile range.
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Among 5780 patients who were followed up <1 year, there
were 2784 of deaths within 1 year of dialysis. Sixty-five percent
of those patients exclusively used a CVC, and they had a lower
survival compared with patients having an initial AVF or AVG
(Supplementary data, Figure S3).
We then conducted subgroup analyses in which we com-
pared each pattern of vascular access type during the first year
of dialysis in models adjusted for case mixþ albumin.
Compared with persistent CVC use, placement of an AVF from
a CVC was associated with a lower mortality risk in all sub-
groups (Figure 3A and Supplementary data, Table S3). In con-
trast, compared with persistent CVC use, placement of an AVG
from a CVC was associated with a similar mortality risk in all
subgroups, except those who were >85 years of age and female
patients, in whom placement of an AVG from a CVC was asso-
ciated with lower mortality (Figure 3B). Compared with persis-
tent CVC use, initial AVF use was associated with a lower
mortality risk in all subgroups, except those who had serum al-
bumin levels3.5g/dL, in whom initial AVF use was associated
with a similar mortality risk (Figure 3C). Compared with persis-
tent CVC use, initial AVG use was associated with lower mor-
tality risk in all subgroups except those who were 80–85 years of
age, males, Whites, nondiabetics, patients without congestive
heart failure, those with Charlson Comorbidity Index scores>7
and those with serum albumin3.5 g/dL (Figure 3D).
Duration of CVC use and mortality risk among elderly
incident hemodialysis patients
We then sought to examine the association of the duration of
CVC use within the first year of dialysis with all-cause mortality
risk among patients 80 years of age. We observed that 26, 20,
17 and 37% of patients had CVC use persisting 3months, <3
to6months,<6 to9months and<9 to12months, respec-
tively. In unadjusted, case mix, case mixþMICS and case
mixþ albumin–adjusted models, longer durations of CVC use
within the first year of dialysis were associated with incrementally
higher mortality risk (Figure 4 and Supplementary data, Table S4).
DISCUSSION
Among a nationally representative cohort of elderly (80 years
of age) incident hemodialysis patients who survived the first
year of dialysis, compared with patients with persistent CVC
use, those with initial AVF or AVG use and placement of an
AVF from a CVC had a lower risk of death, whereas those with
placement of an AVG from a CVC demonstrated similar mor-
tality. When the reference group was changed to patients with
placement of an AVF from a CVC, those with initial AVF use
had a similar mortality risk, whereas those with placement of an
AVG from a CVC had worse survival. Within the same cohort,
we also observed that an incrementally longer duration of CVC
use within the first year of dialysis was associated with increas-
ingly higher mortality risk.
Successful creation of a functioning vascular access is of the
utmost importance to hemodialysis patients, given that it is
their ‘lifeline’ for survival. However, vascular access procedures
and ensuing complications represent a major source of morbid-
ity in this population [22–25]. While it is widely established
that an AVF is a preferred vascular access type given its lower
tendency for infection and thrombosis [6, 26–28] and greater
longevity [8, 9, 29], the use of CVCs among hemodialysis
patients remains high [30, 31]. According to US Renal Data
System data, >80% of incident hemodialysis patients initiate
treatment with a CVC as their primary vascular access [19, 32].
Moreover, a large proportion of hemodialysis patients who ini-
tiate treatment with a CVC do not transition to a permanent
vascular access within 90 days (59%), particularly in older
(>75 years of age) patients [33].
In our study we observed a similar prevalence of placement
of an AVF/AVG from a CVC within 90days of initiating dialy-
sis among patients <80 versus 80 years of age. While place-
ment of an AVF/AVG gradually increased over time, there was
a higher proportion of patients 80 years of age who persisted
in CVC dependency 1 year after dialysis treatment compared
with those<80 years of age.While our study did not specifically
investigate reasons for delayed placement of an AVF from a
CVC, it has been suggested that a greater burden of peripheral
vascular disease as well as suboptimal or absent forearm veins
are risk factors for delayed maturation of AVFs in this popula-
tion [34, 35]. In addition, several aspects of CVCs, including
immediate readiness of use, relative ease of placement and the
absence of pain with cannulation may make this an appealing
vascular access option among elderly hemodialysis patients
with limited life expectancy [5, 36, 37]. Indeed, a recent study
reported that two-thirds of deceased elderly hemodialysis
FIGURE 2: Unadjusted and adjusted HRs and 95% CIs for all-cause
mortality associated with the pattern of vascular access type within the
ﬁrst year of hemodialysis (reference: CVC use only group).
Unadjusted model included the pattern of vascular access use; case
mix–adjusted model included the unadjusted model covariates, as well
as age, sex, race/ethnicity, primary insurance type, comorbid condi-
tions (diabetes mellitus, hypertension, atherosclerotic heart disease,
congestive heart failure, other cardiovascular disease, cerebrovascular
disease, dyslipidemia, chronic obstructive pulmonary disease, liver dis-
ease and history of malignancy) and dialysis dose as measured by sin-
gle-pool Kt/V; case mixþ MICS model included the case mix–
adjusted model covariates, as well as BMI and clinically relevant labo-
ratory variables (WBC count, hemoglobin, serum albumin, creatinine,
bicarbonate, uncorrected calcium, phosphorus, iPTH, total iron bind-
ing capacity and nPCR); case mixþ albumin model included the case
mix–adjusted model covariates, as well as serum albumin.
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FIGURE 3: Forest plot of all-cause mortality associated with vascular access type pattern, categorized as placement of (A) an AVF from a
CVC, (B) a CVC to an AVG, (C) initial AVF use and (D) initial AVG use during the ﬁrst year after hemodialysis initiation (reference: CVC
use only group) across clinically relevant subgroups. Adjusted for case mixþ albumin covariates, including age, sex, race/ethnicity, primary in-
surance type, comorbid conditions (diabetes mellitus, hypertension, atherosclerotic heart disease, congestive heart failure, other cardiovascular
disease, cerebrovascular disease, dyslipidemia, chronic obstructive pulmonary disease, liver disease and history of malignancy), single-pool Kt/
V and serum albumin.
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patients who underwent AVF placement died before use of the
vascular access [35]. Given the unique challenges of immediate
AVF use among elderly hemodialysis patients, we aimed to de-
termine whether initial CVC use with subsequent placement of
an AVF or AVG within 1 year of dialysis initiation was associ-
ated with better survival versus persistent CVC use in this
population.
To our knowledge, this is the first study to demonstrate that
elderly patients who initiated hemodialysis with CVCs yet
underwent placement of an AVF within 1 year had similar sur-
vival compared with those who initiated dialysis using AVFs as
their primary vascular access. In addition, we report for the first
time that a longer duration of CVC use is incrementally associ-
ated with a higher death risk in the elderly hemodialysis popula-
tion. While multiple studies have demonstrated the superiority
of AVFs/AVGs versus CVCs upon survival in elderly hemodial-
ysis patients [13, 38–41], they typically have focused on vascular
access at the time of dialysis initiation and have not been able to
account for confounding on the basis of predialysis care (i.e.
patients who initiated hemodialysis with a functioning AVF/
AVG may have had better access to or compliance with pre-
dialysis nephrology care). It has been suggested that patients’
underlying conditions during the predialysis period have a
greater impact on outcomes than the effect of access itself [18,
42, 43], and the survival benefits of AVFs/AVGs over CVCs
may be minimal among patients who are at higher risk of AVF/
AVG failure (i.e. older age, female, diabetic) [44]. However, we
observed that, compared with persistent CVC use, placement of
an AVF from a CVC within the first year of dialysis was associ-
ated with better survival across all subgroups among elderly he-
modialysis patients.
Debate continues regarding the superiority of AVFs versus
AVGs among elderly hemodialysis patients. Given that AVGs
have comparatively shorter maturation times and lower rates of
primary failure, it has been suggested that they may be a more
suitable vascular access option among elderly patients with a
higher likelihood of vascular insufficiency and limited life ex-
pectancy [34, 37]. Recent data also suggest that AVGs are asso-
ciated with similar microorganism detection rates and survival
as compared with AVFs in elderly hemodialysis patients [5].
However, we observed that placement of an AVG from a CVC
was associated with similar mortality risk as with persistent
CVC use and higher mortality risk compared with placement of
an AVF from a CVC among the oldest hemodialysis patients.
These observations may potentially be explained by the poorer
long-term patency and higher risk of complications of AVGs
versus AVFs, including thrombosis and infection, leading to a
greater number of secondary interventions that may carry po-
tential risk in elderly hemodialysis patients [45, 46]. Given that
age has not been found to be a potent determinant of AVF pa-
tency across multiple studies [47–50], it may be inferred from
our data that AVF should remain as the preferred vascular ac-
cess type in this population. However, among patients in whom
there may be a delay in placement of an AVF from a CVC due
to poor maturation or primary access failure, given the high
mortality risk observed with a longer duration of CVC use,
AVGsmay need to be considered as a viable option.
The strengths of our study include its examination of a large,
nationally representative cohort of dialysis patients, examina-
tion of incident hemodialysis patients whose characteristics are
not confounded by survivor bias and the comprehensive avail-
ability of detailed, longitudinal patient-level comorbidity, labo-
ratory and dialysis-treatment data, including vascular access
type. However, several limitations bear mentioning. First, we
lacked information on the status of access such as blood flow
rate and secondary vascular access complications, including
vascular access thrombosis, infection, and nonmaturation, as
well as interventions. Second, we were unable to account for the
access creation process, such as who was responsible for access
creation and confounding on the basis of surgeon experience
and training. Third, due to data limitations, we could not exam-
ine cause-specific mortality (e.g. infection-related mortality) to
better elucidate underlying mechanisms of the vascular access
type–mortality association. Fourth, the analysis was restricted
to patients who survived at least 1 year following dialysis initia-
tion in order to ascertain vascular access patterns over this pe-
riod. Lastly, as with all observational studies, our study does not
confirm a causal association between patterns of vascular access
and mortality.
In conclusion, among incident hemodialysis patients
80 years of age, compared with patients with persistent CVC
use, placement of an AVF from a CVC was associated with
≤3m <3 to ≤6m <6 to ≤9m <9 to ≤12m
FIGURE 4: Unadjusted and adjusted HRs and 95% CIs for all-cause
mortality associated with the duration of CVC use for hemodialysis
within 1 year after dialysis initiation (reference: CVC use
3months). Unadjusted model included the pattern of vascular ac-
cess use; case mix–adjusted model included the unadjusted model
covariates, as well as age, sex, race/ethnicity, primary insurance type,
comorbid conditions (diabetes mellitus, hypertension, atherosclerotic
heart disease, congestive heart failure, other cardiovascular disease,
cerebrovascular disease, dyslipidemia, chronic obstructive pulmo-
nary disease, liver disease and history of malignancy) and dialysis
dose as measured by single-pool Kt/V; case mixþMICS model in-
cluded the case mix–adjusted model covariates, as well as BMI and
clinically relevant laboratory variables (WBC count, hemoglobin, se-
rum albumin, creatinine, bicarbonate, uncorrected calcium, phos-
phorus, iPTH, total iron binding capacity and nPCR); case
mixþ albumin model: included the case mix–adjusted model covari-
ates, as well as serum albumin.
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lower mortality risk, whereas those who had placement of an
AVG from a CVC had a similar mortality risk. We also ob-
served that with placement of an AVF from a CVC was associ-
ated with similar mortality as compared with initial AVF use in
this population. Moreover, we found that an incrementally lon-
ger duration of CVC use within the first year of dialysis was as-
sociated with increasingly higher mortality risk among patients
80 years of age. Future studies are needed to determine the
underlying mechanisms and to develop individualized vascular
access management strategies among specific patient
populations.
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